Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
收藏数据链接：
官方服务：
资源简介：
Summary of best overall response and objective response (confirmed) based on investigator assessment (RECIST version 1.1)—response-evaluable set, part 2.
创建时间：
2025-07-15
